High-Performance Computing (HPC) storage and data analytics integrator, OCF, is supporting scientific research at the UK Atomic Weapons Establishment (AWE), with the design, testing and implementation of a new HPC, cluster and separate big data storage system
Robert Roe investigates the use of technologies in HPC that could help shape the design of future supercomputers
David Yip gives his take on the HPC processor market.
HPC, storage and data analytics integrator, OCF, has acquired a majority share of Intense Computing, a provider of data and analytics consultancy and solutions. Intense Computing will be a subsidiary company of OCF and is being renamed OCF DATA Limited, strengthening and enhancing OCF’s data and analytics service for customers.
We have a strong reputation as the UK’s trusted high performance server and storage cluster integrator; we provide cluster services and support to ensure integration success. For customers who want easy access to HPC without the need for resource in-house we also provide a cloud, Infrastructure as a Service to meet their data processing requirements with minimal capital expenditure. Read more about the enCORE HPC on-demand service.
Imperial College London uses new Half PB storage to support research and e-learning
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
